Tandem Diabetes Care is conducting an observational research study involving people with type 1 diabetes to understand their experiences using the t:slim X2 insulin pump with Control-IQ technology. Data collected will help determine how well Control-IQ software is working for people in the real world. This study is approved by an IRB (Institutional Review Board) and the FDA (Federal Drug Administration). During this 12-month study, we will collect information on:
If your healthcare provider has sent in your prescription for the t:slim X2 insulin pump with Control-IQ technology but you have not yet started using the system, then you are eligible for this study. Qualifying participants also must be able to answer “yes” to all of the following statements.
Here is what qualifying participants will experience if they join this study:
Participation in this study is voluntary and participants can decide to leave the study at any time. An individual’s participation in this study does not influence their ability to continue to use Tandem products, purchase any supplies, or have full support from the Tandem customer care team.
If you qualify for this study, you will automatically receive an email invitation from Tandem Diabetes Care once we receive your prescription for Control-IQ technology. If you do not receive an invitation but think you qualify and would like to learn more, please contact Tandem Diabetes Care.